X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

AMR Is The Main Focus of New Research Consortium In World

Content Team by Content Team
2nd May 2023
in News, Research & Development

Global research consortium is being set up to address the international impact of antimicrobial resistance (AMR). Significantly, the Centres for Antimicrobial Optimisation Network- CAMO-Net brings together research team from South Africa’s University of Cape Town, the University of Liverpool as well as Imperial College, London, the Ugandan Infectious Disease Institute, as well as the faculty of medicine at Brazil’s University of Sao Paulo.

CAMO-Net looks to optimise antimicrobial usage in humans by way of a sustainable global research spectrum that is developed across low, middle, and high resource settings throughout the rural as well as urban landscape. The University of Liverpool’s Professor Alison Holmes and Imperial College London in the UK declared that not only is this network going to provide a one-off unique opportunity so as to advance the multidisciplinary research to improve as well as sustain access to antimicrobial treatments that are effective and also address AMR, it has also shared the global learning embedded within it and also goes on to represent a significant commitment when it comes to research models that are more equitable.

Researchers will work towards building knowledge when it comes to optimal antibiotic usage, enhanced access to treatment that’s effective, and better prevention and treatment of bacterial infections. This initiative will help enhance clinical decision-making when it comes to antimicrobial usage and also help prescribers, policymakers, and users with practises and guidelines.

The Executive Director, Infectious Disease Institute in Uganda, called the country’s engagement in the CAMO-Net pathbreaking and an opportunity to generate research so as to help in overcoming AMR across the region.

The consortium’s main operations will be spread across regions that have a very high burden of drug-resistant infections while also making use of a multi-sectoral and system-based approach to enhancing antimicrobial usage. CAMO-Net is going to work with its collaborators in order to research how to actionably enhance antimicrobial use in humans via three inter-linked themes that are identified via the Wellcome-commisioned roadmap.

The four sites constitute national hubs that are responsible for driving the research and spearheading the global network. Each hub happens to have specific as well as complementary research expertise and shall go on to receive exclusive funding with awards, thereby linking directly with that of the other three countries.

The objective is to improve research equity by ensuring local leadership and encouraging joint ownership within the programmes. These constituents happen to be forming the core value of the consortium in sync with knowledge mobilisation, mutually beneficial cross-regional learning, and output sharing. The network looks to build a complete contextual understanding when it comes to situational data across each national hub so as to pinpoint opportunities and also address challenges as well as gaps.

CAMO-Net will also include 3 shadow national sites that will go on to participate in network activities and also build a project that happens to be a part of a larger CAMO-Net programme.

Previous Post

Gene Silencing Alzheimers Drug, A World First, Shows Promise

Next Post

EU Drug Manufacturing Law Changes Disappoint Manufacturers

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Next Post

EU Drug Manufacturing Law Changes Disappoint Manufacturers

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In